|
1
|
Castro FA, Koshiol J, Hsing AW and Devesa
SS: Biliary tract cancer incidence in the United States-demographic
and temporal variations by anatomic site. Int J Cancer.
133:1664–1671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Konishi M, Ochiai A, Ojima H, Hasebe T,
Mano M, Ohta T, Ito I, Sasaki K, Yasukawa S, Shimada K, et al: A
new histological classification for intra-operative histological
examination of the ductal resection margin in cholangiocarcinoma.
Cancer Sci. 100:255–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Konishi M, Iwasaki M, Ochiai A, Hasebe T,
Ojima H and Yanagisawa A: Clinical impact of intraoperative
histological examination of the ductal resection margin in
extrahepatic cholangiocarcinoma. Br J Surg. 97:1363–1368. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakanishi Y, Kondo S, Zen Y, Yonemori A,
Kubota K, Kawakami H, Tanaka E, Hirano S, Itoh T and Nakanuma Y:
Impact of residual in situ carcinoma on postoperative survival in
125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary
Pancreat Sci. 17:166–173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ribero D, Amisano M, Lo Tesoriere R, Rosso
S, Ferrero A and Capussotti L: Additional resection of an
intraoperative margin-positive proximal bile duct improves survival
in patients with hilar cholangiocarcinoma. Ann Surg. 254:776–783.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsuda Y, Yamamoto T, Kudo M, Kawahara K,
Kawamoto M, Nakajima Y, Koizumi K, Nakazawa N, Ishiwata T and Naito
Z: Expression and roles of lumican in lung adenocarcinoma and
squamous cell carcinoma. Int J Oncol. 33:1177–1185. 2008.PubMed/NCBI
|
|
7
|
Miyazaki M, Ohtsuka M, Miyakawa S, Nagino
M, Yamamoto M, Kokudo N, Sano K, Endo I, Unno M, Chijiiwa K, et al:
Classification of biliary tract cancers established by the Japanese
Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English
edition. J Hepatobiliary Pancreat Sci. 22:181–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kayahara M, Nagakawa T, Ohta T, Kitagawa
H, Tajima H and Miwa K: Role of nodal involvement and the
periductal soft-tissue margin in middle and distal bile duct
cancer. Ann Surg. 229:76–83. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burke EC, Jarnagin WR, Hochwald SN,
Pisters PW, Fong Y and Blumgart LH: Hilar Cholangiocarcinoma:
Patterns of spread, the importance of hepatic resection for
curative operation and a presurgical clinical staging system. Ann
Surg. 228:385–394. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DeOliveira ML, Cunningham SC, Cameron JL,
Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick
RD: Cholangiocarcinoma: Thirty-one-year experience with 564
patients at a single institution. Ann Surg. 245:755–762. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kondo S, Takada T, Miyazaki M, Miyakawa S,
Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M,
et al: Guidelines for the management of biliary tract and ampullary
carcinomas: Surgical treatment. J Hepatobiliary Pancreat Surg.
15:41–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhuiya MR, Nimura Y, Kamiya J, Kondo S,
Nagino M and Hayakawa N: Clinicopathologic factors influencing
survival of patients with bile duct carcinoma: Multivariate
statistical analysis. World J Surg. 17:653–657. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M,
Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D and Blumgart
LH: Staging, resectability, and outcome in 225 patients with hilar
cholangiocarcinoma. Ann Surg. 234:507–519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Igami T, Nagino M, Oda K, Nishio H, Ebata
T, Yokoyama Y and Shimoyama Y: Clinicopathologic study of
cholangiocarcinoma with superficial spread. Ann Surg. 249:296–302.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakanishi Y, Zen Y, Kawakami H, Kubota K,
Itoh T, Hirano S, Tanaka E, Nakanuma Y and Kondo S: Extrahepatic
bile duct carcinoma with extensive intraepithelial spread: A
clinicopathological study of 21 cases. Mod Pathol. 21:807–816.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ojima H, Kanai Y, Iwasaki M, Hiraoka N,
Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Sakamoto M and
Hirohashi S: Intraductal carcinoma component as a favorable
prognostic factor in biliary tract carcinoma. Cancer Sci.
100:62–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Endo I, House MG, Klimstra DS, Gonen M,
D'Angelica M, Dematteo RP, Fong Y, Blumgart LH and Jarnagin WR:
Clinical significance of intraoperative bile duct margin assessment
for hilar cholangiocarcinoma. Ann Surg Oncol. 15:2104–2112. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okazaki Y, Horimi T, Kotaka M, Morita S
and Takasaki M: Study of the intrahepatic surgical margin of hilar
bile duct carcinoma. Hepatogastroenterology. 49:625–627.
2002.PubMed/NCBI
|
|
19
|
Baton O, Azoulay D, Adam DV and Castaing
D: Major hepatectomy for hilar cholangiocarcinoma type 3 and 4:
Prognostic factors and longterm outcomes. J Am Coll Surg.
204:250–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakamoto E, Nimura Y, Hayakawa N, Kamiya
J, Kondo S, Nagino M, Kanai M, Miyachi M and Uesaka K: The pattern
of infiltration at the proximal border of hilar bile duct
carcinoma: A histologic analysis of 62 resected cases. Ann Surg.
227:405–411. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JH, Hwang DW, Lee SY, Park KM and Lee
YJ: The proximal margin of resected hilar cholangiocarcinoma: The
effect of microscopic positive margin on long-term survival. Am
Surg. 78:471–477. 2012.PubMed/NCBI
|
|
22
|
Konstantinos K, Marios S, Anna M, Nikolaos
K, Efstratios P and Paulina A: Expression of Ki-67 as proliferation
biomarker in imprint smears of endometrial carcinoma. Diagn
Cytopathol. 41:212–217. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Isola J, Helin H and Kallioniemi OP:
Immunoelectron-microscopic localization of a
proliferation-associated antigen Ki-67 in MCF-7 cells. Histochem J.
22:498–506. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verheijen R, Kuijpers HJ, Schlingemann RO,
Boehmer AL, van Driel R, Brakenhoff GJ and Ramaekers FC: Ki-67
detects a nuclear matrix-associated proliferation-related antigen.
I. Intracellular localization during interphase. J Cell Sci.
92:123–130. 1989.PubMed/NCBI
|
|
25
|
Rufini A, Tucci P, Celardo I and Melino G:
Senescence and aging: The critical roles of p53. Oncogene.
32:5129–5143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basu A and Haldar S: The relationship
between BcI2, Bax and p53: Consequences for cell cycle progression
and cell death. Mol Hum Reprod. 4:1099–1109. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: Clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
28
|
Hussain SP and Harris CC: Molecular
epidemiology of human cancer: Contribution of mutation spectra
studies of tumor suppressor genes. Cancer Res. 58:4023–4037.
1998.PubMed/NCBI
|
|
29
|
Kang YK, Kim WH and Jang JJ: Expression of
G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in
intrahepatic cholangiocarcinoma. Hum Pathol. 33:877–883. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harris CC: Structure and function of the
p53 tumor suppressor gene: Clues for rational cancer therapeutic
strategies. J Natl Cancer Inst. 88:1442–1455. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levine AJ: The p53 tumor-suppressor gene.
N Engl J Med. 326:1350–1352. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diamantis I, Karamitopoulou E, Perentes E
and Zimmermann A: p53 protein immunoreactivity in extrahepatic bile
duct and gallbladder cancer: Correlation with tumor grade and
survival. Hepatology. 22:774–779. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jan YY, Yeh TS, Yeh JN, Yang HR and Chen
MF: Expression of epidermal growth factor receptor, apomucins,
matrix metalloproteinases, and p53 in rat and human
cholangiocarcinoma: Appraisal of an animal model of
cholangiocarcinoma. Ann Surg. 240:89–94. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi
M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al:
Ki-ras mutations and p53 protein expressions in intrahepatic
cholangiocarcinomas: relation to gross tumor morphology.
Gastroenterology. 109:1612–1617. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tannapfel A, Engeland K, Weinans L,
Katalinic A, Hauss J, Mössner J and Wittekind C: Expression of p73,
a novel protein related to the p53 tumour suppressor p53, and
apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer.
80:1069–1074. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Teh M, Wee A and Raju GC: An
immunohistochemical study of p53 protein in gallbladder and
extrahepatic bile duct/ampullary carcinomas. Cancer. 74:1542–1545.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Washington K and Gottfried MR: Expression
of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver.
16:99–104. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Labib PL, Davidson BR, Sharma RA and
Pereira SP: Locoregional therapies in cholangiocarcinoma. Hepat
Oncol. 4:99–109. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shinohara E, Mitra N, Guo M and Metz J:
Radiation therapy is associated with improved survival in the
adjuvant and definitive treatment of intrahepatic
cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 72:1495–1501.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Siebenhüner AR, Seifert H, Bachmann H,
Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA,
Stupp R, Knuth A, et al: Adjuvant treatment of resectable biliary
tract cancer with cisplatin plus gemcitabine: A prospective single
center phase II study. BMC Cancer. 18:722018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Horgan AM, Amir E, Walter T and Knox JJ:
Adjuvant therapy in the treatment of biliary tract cancer: A
systematic review and meta-analysis. J Clin Oncol. 30:1934–1940.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McNamara MG, Walter T, Horgan AM, Amir E,
Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M,
et al: Outcome of adjuvant therapy in biliary tract cancers. Am J
Clin Oncol. 38:382–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stein A, Arnold D, Bridgewater J,
Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J,
Schrum S, et al: Adjuvant chemotherapy with gemcitabine and
cisplatin compared to observation after curative intent resection
of cholangiocarcinoma and muscle invasive gallbladder carcinoma
(ACTICCA-1 trial)-a randomized, multidisciplinary, multinational
phase III trial. BMC Cancer. 15:5642015. View Article : Google Scholar : PubMed/NCBI
|
